This product is not currently available
The Now Generation & New Generation of GLP-1 RAs: Reshaping the Care of T2DM



1.25 hours of AMA PRA Category 1 Credit™


Live Webinars
Internationally renowned faculty will provide updates on the latest clinical trials on long-acting glucagen-like peptide-1 receptor agonists(GLP-1 RAs), findings that may serve as the impetus for important changes in European and Canadian treatment guidelines for the management of T2DM.


  The New Generation of Glycemic Management in Diabetes
Two key members of the Diabetes Canada treatment guidelines panel provide primary providers throughout Canada with the tips and tools to help them navigate the 2018 guideline changes, and present clinical trials data on long-acting GLP-1 RAs that may change the way you practice.

Ronald M. Goldenberg, MD
North York General Hospital
  and LMC Diabetes & Endocrinology
Thornhill, Ontario, Canada

Dr. Goldenberg is an advisory board member for Amgen, Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi, Takeda, and Valeant; is a member of the Amgen, Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Mylan, Novo Nordisk, Sanofi, Servier, and Valeant Speakers' Bureaus; has received/is receiving a grant or an honorarium from Antibody, CCRN, Toronto Knowledge Translation Working Group, Master Clinician Alliance, mdBriefCase, Script Medical, EOCI Pharmacomm, Agora, STA, CMS Canada, Inceptus, Med Plan, and Haymarket. He has participated in clinical trials within the past 2 years for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi, and Takeda.


Robyn L. Houlden, MD, FRCPC
Chair, Diabetes Canada Clinical Practice Guidelines Expert Committee
Professor and Chair of Endocrinology
Queen's University
Kingston, Ontario, Canada

Dr. Houlden is a member of the Eli Lilly and Novo Nordisk Speakers' Bureaus. She has participated in clinical trials within the past 2 years for AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk.


  GLP-1 Receptor Agonists in Clinical Practice
Drs. Lorraine Lipscombe and Caroline Kramer outline the appropriate role for once-weekly GLP-1 RAs; review head-to-head data on glycemic efficacy, weight loss and cardiovascular outcomes; and underscore key aspects of patient selection and shared decision-making.

Caroline Kramer, MD, PhD
Assistant Professor and Clinician-Scientist
Division of Endocrinology
University of Toronto
Leadership Sinai Centre for Diabetes
Mount Sinai Hospital

Dr. Kramer has received/is receiving a grant or an honorarium from Boehringer Ingelheim.


Lorraine Lipscombe, MD, MSc, FRCPC
Director of Endocrinology
Women’s College Hospital
University of Toronto
Toronto, Ontario, Canada

Dr. Lipscombe has received/is receiving a grant or an honorarium from Diabetes Canada.


Once-Weekly GLP-1 RAs: Shaping the Direction of the ADA/EASD Guidelines
Professors Melanie Davies and Chantel Mathieu, principal authors of the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) 2018 Consensus Report on the Management of Hyperglycemia in Type 2 Diabetes, present a wide ranging discussion on the guidelines recommendations, and offer insights into the latest generation of GLP-1 RA, and how they fit into treatment decisions now and in the future.

Melanie J. Davies, CBE, MB, ChB MD, FRCP, FRCGP
Diabetes Research Center, University of Leicester
Leicester Diabetes Centre
Leicester General Hospital
Leicester, England, UK

Professor Davies has acted as consultant and advisory board member for Novo Nordisk, Sanofi-Aventis, and Lilly, and as an advisory board member for Servier and Janssen; on the Speakers' Bureau for Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer lngelheim, and Takeda Pharmaceuticals International Inc.; and acted as a principal investigator where grants have been received in support of investigator and/or investigator-initiated trials from Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer lngelheim, and Janssen.


Chantal Mathieu, MD, PhD
Clinical and Experimental Endocrinology
UZ Gasthuisberg, KU Leuven
Leuven, Belgium

Professor Mathieu has served on advisory panels for, and has been a speaker or received research support from Adocia, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Dianax, Eli Lilly, GSK, Intrexon, Janssen, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics, and Sanofi.


It's Not Just About Glycemic Control: Once-Weekly GLP-1 RAs and the Diversity of T2DM Patients
Two preeminent endocrinologists provide practicing clinicians throughout Europe with a comprehensive evaluation of the impact of next generation long-acting GLP-1 RAs on glycemic control, body weight, and cardiovascular risk reduction.

Stephen C. Bain, MD
Professor of Medicine (Diabetes)
Swansea University Medical School
Sketty, Swansea
England, UK

Professor Bain received/receives consulting fees from Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Napp, AstraZeneca, MSD, and Sanofi-Aventis.


Michael Nauck, MD
Diabetes Center Bochum‐Hattingen
St. Josef Hospital, Ruhr‐University Bochum
Bochum, Germany

Professor Nauck receives consulting fees from AstraZeneca, Boehringer lngelheim, Menarini/Berlin-Chemie, Eli Lilly, Fractyl, GSK, MSD, Novo Nordisk, Sanofi-Aventis, Sun Pharma, and Medscape; is on the Speakers' Bureaus for AstraZeneca, Menarini/Berlin-Chemie, Eli Lilly, GSK, Medscape, MSD, Novo Nordisk, Sanofi, and Sun Pharma; performed contracted research for Eli Lilly, GSK, Menarini/Berlin-Chemie, MSD, Novartis, and Novo Nordisk (to his institution).


Target Audience
Endocrinologists, primary care clinicians (e.g., internists, family medicine/family practice/general practitioners, nurse practitioners [NPs], and physician assistants [PAs]), diabetes specialists, and other providers who care for patients with diabetes and practice in Europe and Canada.


Learning Objectives
After participating in these educational activities, clinicians should be better able to:

  • Define an appropriate role for GLP-1 RAs in the multidimensional care of the patient with T2DM
  • Compare the current generation of once-weekly GLP-1 RAs re: glycemic efficacy, weight-loss efficacy, and safety, citing latest available data in clinical trials
  • Describe key aspects of the next generation of GLP-1 RAs (e.g., route of administration, MOA, absorption, PK/PD, etc.), including clinical trials data on efficacy and safety
  • Summarize ADA/EASD and Canadian guideline updates for 2018 and their practical impact on clinical decision-making
  • Engage in a therapeutic alliance with patients, applying the principles of shared decision-making in a collaborative model of diabetes care



By Internet Only: View presentation slides online while listening to the audio on your computer. Submit your questions via the Internet.

Internet and Telephone: View presentation slides online while listening on the phone. Submit your questions via the Internet or the phone.


At the bottom of the page please select which webinars you wish to attend, click Add to Cart, and complete the form on the next page. Registration is required for any of these complimentary web conferences. You will receive an email confirmation of registration with your instructions on how to participate. If you do not receive a confirmation within 24 hours, please call 866-872-5840. Registration and CME/CPD credits are free for participants.


Accreditation / Designation Statement(s)
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Haymarket Medical Education designates each of these live activities for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.




The Providers certify that the educational activities will comply with all applicable current ethics guidelines, codes and regulations related to CME, including but not limited to, UEMS EACCME Guidelines for Commercial Support and Recommendations for CME Providers, Danish ENLI Code, LIF, and the Canadian National Standard for support of Accredited CPD Activities.


After participating in each of these live activities, complete and submit the posttest and evaluation forms. Upon successful completion of the posttest with a score of at least 70% correct, a certificate of completion will be issued to you for your records.



Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.

Estimated time to complete each activity is 75 minutes.

Bundled Products

Jointly provided by
Supported by an
educational grant from
Novo Nordisk